You make a completely fair point that once a branded, new medicine is available, there will come a period of time when generic ones are available, and it's work we've actually done across the whole service on making sure that generic products are used in preference wherever possible, because it doesn't remove the value, it improves the value, and it doesn't in any way diminish the efficacy of those drugs.

You make an interesting point about what happens if you see a reduction in a product that is particularly aimed at one area of the service and whether the savings for generic medicine should be retained in that service. What I would say is that I think that we want to make sure we provide equitable access to the best quality treatment, and I would be reticent about taking an approach that might be replicated in other parts of the service that mean we can't mean move funds around where we need to have them, but it would not lessen the importance of making sure we have an effective sexual health service so that we continue on the trajectory of trying to make sure that we meet the World Health Organization's ambition that we become HIV-free at the nearest possible point in the future.